Clinical trial
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
NCT00100828 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Terminated
Key facts
| NCT number | NCT00100828 |
|---|---|
| Title | Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer |
| Official title | Phase II Trial of Irinotecan for Treatment of Metastatic Medullary Thyroid Cancer |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Enrollment | 6 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jan 7, 2005 |
| Last update posted | Dec 6, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: